Cancer Immunotherapy & Immunomonitoring

May 2-5, 2011
Budapest, Hungary

Plenary sessions:

- Inflammation and immunity in the tumor microenvironment
- Regulatory and effector mechanisms in the tumor environment 
- Tumor microenvironment and cancer immunotherapy
- Preclinical models of cancer immunotherapy
- Cancer immunotherapy in pediatric oncology 
- Cancer immunotherapy: Regulatory cells and cytokines
- Cancer immunotherapy: New approaches
- Cancer biomarkers and immunomonitoring in cancer clinical trials

Best ABSTRACTS will be selected for ORAL PRESENTATION!


Social sessions:

- Visit St. Stephan’s Basilica, Margaret Island, Central Market and Váci street
- Try Goulash soup and Pörkölt
- Dip in the Széchenyi Baths
- Try the Hungarian wines, Pálinka and the Unicum
- Go to a typical Budapest-pub in the former Jewish District
- Have Dobostorta
- Visit National Museum, Holocaust Museum, Museum of Fine Arts and Dreher Beer Museum
- Enjoy the best panoramas of Budapest from Gellért's Hill

Malcolm Brenner, Baylor College of Medicine, USA, Keynote Speaker

Dmitry Gabrilovich, H.Lee Moffitt Cancer Center, USA, Keynote Speaker

Robert Wiltrout, CCR, NCI, NIH, USA, Keynote Speaker

Isaak Witz, Tel Aviv University, Israel, Keynote Speaker

John Anderson, UCL Institute of Child Health,  UK

Natalia Aptsiauri, Univesity of Granada, Spain

Ron Apte, Ben Gurion University, Israel

Paolo A. Ascierto, Istituto Nazionale Tumori in Naples, Italy

Michal Baniyash, Hebrew University, Israel

Philipp Beckhove, German cancer Research Center, Germany

Luigi Buonaguro, Istituto Nazionale Tumori in Naples, Italy

Alessandra Cesano, Nadality, Inc.,  USA

Gurkamal Chatta, University of Pittsburgh Cancer Institute, USA

Laurence Cooper, MD Anderson Cancer Center, USA

Gianpietro Dotti, Baylor College of Medicine, USA

Andr&aacutes Falus, Semmelweis University, Hungary

Udo S. Gaipl, University Hospital Erlangen, Germany

Federico Garrido, Hospital Univ Virgen de las Nieves, Spain

Ronald Gress, NCI, NIH, USA

Arthur A. Hurwitz, NCI, NIH, USA

Ramon Kaneno, Sao Paulo University, Brazil

Beatrix Kotlan, National Institute of Oncology, Hungary

Claude Leclerc, Institut Pasteur, France

Paul V. Lehmann, Cellular Technology Limited, USA

Holger Lode, Charite Universitatsmediz, Germany

Joseph Lustgarten, Cancer Center Scottsdale, USA

Anatoli M. Malyguine, SAIC-Frederick, Inc., NCI, NIH, USA

Franco Marincola, NIH, NCI, USA

Leonid S. Metelitsa, Baylor College of Medicine, USA

John C. Morris, NIH, NCI, USA

William Murphy, University of California Davis, USA

Sattva S. Neelapu, MD Anderson Cancer Center, USA

Suzanne Ostrand-Rosenberg, University of Maryland, USA

Graham Pawelec, University of T&uumlbingen Medical School, Germany

Angel Porgador, Ben Gurion University, Israel

Mepur Ravindranath, Terasaki Foundation Laboratory, USA

Licia Rivoltini, Istituto Nazionale Tumori in Milan, Italy

Philip Savage, Charing Cross Hospital, UK

Tomas Sayers, NIH, NCI, USA

Barbara Seliger, University Halle-Wittenberg, Germany

Yehuda Shoenfeld, Sheba Medical Center, Israel

Galina V. Shurin, University of Pittsburgh, USA

Michael R. Shurin, University of Pittsburgh, USA

Benjamin Sredni, Bar Ilan University, Israel

Perthor Straten, University Hospital Herlev, Denmark

Zolt&aacuten Szekanecz, University of Debrecen Medical Center, Hungary

Jozsef Timar, Semmelweis University, Hungary

Viktor Umansky, German Cancer Research Center, Germany

Luca Vannucci, Rep Inst for Microbiology, Natl Acad Sci, Czech

Elana Voronov, Ben Gurion University, Israel

Theresa Whiteside, Univ of Pittsburgh Cancer Institute, USA

Eitan Yefenof, Hebrew University, Israel

Dov Zipori, Weizmann Institute of Science, Israel